Business Context and Reporting Period
This Form 8-K filing by SELLAS Life Sciences Group, Inc. (SLS) was submitted on March 5, 2024. The report addresses a specific regulatory event regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only quantitative data provided relates to listing compliance:
- Market Value of Listed Securities (MVLS): Greater than $35.0 million (calculated as total shares outstanding multiplied by the closing bid price per share).
- Compliance Duration: Maintained for the last 10 consecutive business days prior to the filing date.
Material Changes
The primary material change is the resolution of a prior non-compliance issue:
- Previous Status: On December 6, 2023, the company received notice of non-compliance with Nasdaq Listing Rule 5550(b)(2) because the MVLS had fallen below $35.0 million for 30 consecutive business days.
- Current Status: The company has regained compliance with the MVLS Rule. Nasdaq has officially closed the matter.
- Compliance Period: The company was previously granted an initial 180-day period (until June 3, 2024) to regain compliance, which has now been successfully achieved ahead of the deadline.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks. The document confirms that the risk of delisting due to failure to meet the minimum market value requirement has been mitigated as of the filing date.
Investor Verification Checklist
- Verify the current share price and outstanding share count to confirm the MVLS remains above the $35.0 million threshold.
- Review the December 6, 2023, Nasdaq notice to understand the full context of the prior non-compliance period.
- Monitor future 8-K filings for any new notices regarding listing standards or financial performance.